True Wealth Design’s Pacific Biosciences PACB Stock Holding History

True Wealth Design’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$614	Buy	365 +95	+35%	+$138	﹤0.01%	2131
2026 Q1	$357	Buy	270 +166	+160%	+$297	﹤0.01%	2167
2025 Q4	$195	Hold	104	–	–	﹤0.01%	2233
2025 Q3	$134	Hold	104	–	–	﹤0.01%	2396
2025 Q2	$129	Buy	+104	New	+$120	﹤0.01%	2183

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

True Wealth Design's PACB Position: Q2 2026 in Review

True Wealth Design increased its Pacific Biosciences (PACB) stake by 35% in Q2 2026, buying an estimated $138 and bringing the position to 365 shares worth $614. The position accounts for ﹤0.01% of the portfolio, ranked #2131.

True Wealth Design first reported a position in PACB in Q2 2025 and has held it in 5 quarters since. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

True Wealth Design held 365 shares of Pacific Biosciences worth $614 as of Q2 2026.
True Wealth Design bought 95 Pacific Biosciences shares in Q2 2026, an estimated $138.
Pacific Biosciences made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2131 holding.
True Wealth Design first reported a position in Pacific Biosciences in Q2 2025 and has held it in 5 quarters since.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.